Literature DB >> 33035368

Dupilumab probably reduces transepidermal water loss but does not increase stratum corneum hydration in atopic dermatitis.

Takuya Furuhashi1, Takao Oda2, Kan Torii2, Emi Nishida2, Akimichi Morita2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33035368      PMCID： PMC7891664          DOI： 10.1111/1346-8138.15638

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  5 in total

1.  Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.

Authors:  Kenji Kabashima; Takayo Matsumura; Hiroshi Komazaki; Makoto Kawashima
Journal:  N Engl J Med       Date:  2020-07-09       Impact factor: 91.245

2.  Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.

Authors:  Amy S Paller; Elaine C Siegfried; Diamant Thaçi; Andreas Wollenberg; Michael J Cork; Peter D Arkwright; Melinda Gooderham; Lisa A Beck; Mark Boguniewicz; Lawrence Sher; Jamie Weisman; John T O'Malley; Naimish Patel; Megan Hardin; Neil M H Graham; Marcella Ruddy; Xian Sun; John D Davis; Mohamed A Kamal; Faisal A Khokhar; David M Weinreich; George D Yancopoulos; Bethany Beazley; Ashish Bansal; Brad Shumel
Journal:  J Am Acad Dermatol       Date:  2020-06-20       Impact factor: 11.527

3.  Handheld confocal Raman spectroscopy (CRS) for objective assessment of skin barrier function and stratification of severity in atopic dermatitis (AD) patients.

Authors:  Chris Jun Hui Ho; Yik Weng Yew; U S Dinish; Amanda Hui Yu Kuan; Melvin Kai Weng Wong; Renzhe Bi; Kapil Dev; Xiuting Li; Gurpreet Singh; Mohesh Moothanchery; Jayakumar Perumal; Steven Tien Guan Thng; Malini Olivo
Journal:  J Dermatol Sci       Date:  2020-02-04       Impact factor: 4.563

Review 4.  Dupilumab: A review of its use in the treatment of atopic dermatitis.

Authors:  Melinda J Gooderham; H Chih-Ho Hong; Panteha Eshtiaghi; Kim A Papp
Journal:  J Am Acad Dermatol       Date:  2018-03       Impact factor: 11.527

5.  Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.

Authors:  M J Cork; D Thaçi; L F Eichenfield; P D Arkwright; T Hultsch; J D Davis; Y Zhang; X Zhu; Z Chen; M Li; M Ardeleanu; A Teper; B Akinlade; A Gadkari; L Eckert; M A Kamal; M Ruddy; N M H Graham; G Pirozzi; N Stahl; A T DiCioccio; A Bansal
Journal:  Br J Dermatol       Date:  2019-10-08       Impact factor: 9.302
  5 in total
  2 in total

1.  Dupilumab Improves Skin Barrier Function in Adults with Atopic Dermatitis: A Prospective Observational Study.

Authors:  Trinidad Montero-Vilchez; Juan-Angel Rodriguez-Pozo; Pablo Diaz-Calvillo; Maria Salazar-Nievas; Jesús Tercedor-Sanchez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

Review 2.  Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?

Authors:  Giulia Calabrese; Gaetano Licata; Alessio Gambardella; Alina De Rosa; Roberto Alfano; Giuseppe Argenziano
Journal:  Dermatol Pract Concept       Date:  2022-01-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.